Standard
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. / Olsen, Ingrid Holst; Langer, Seppo W; Jepsen, Ida; Assens, Maria; Federspiel, Birgitte; Hasselby, Jane Preuss; Hansen, Carsten Palnaes; Kjaer, Andreas; Knigge, Ulrich.
In:
Acta Oncologica, Vol. 51, No. 1, 2012, p. 97-100.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Olsen, IH, Langer, SW, Jepsen, I, Assens, M, Federspiel, B, Hasselby, JP, Hansen, CP
, Kjaer, A & Knigge, U 2012, '
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience',
Acta Oncologica, vol. 51, no. 1, pp. 97-100.
https://doi.org/10.3109/0284186X.2011.582881APA
Olsen, I. H., Langer, S. W., Jepsen, I., Assens, M., Federspiel, B., Hasselby, J. P., Hansen, C. P.
, Kjaer, A., & Knigge, U. (2012).
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
Acta Oncologica,
51(1), 97-100.
https://doi.org/10.3109/0284186X.2011.582881Vancouver
Olsen IH, Langer SW, Jepsen I, Assens M, Federspiel B, Hasselby JP et al.
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
Acta Oncologica. 2012;51(1):97-100.
https://doi.org/10.3109/0284186X.2011.582881Author
Olsen, Ingrid Holst ; Langer, Seppo W ; Jepsen, Ida ; Assens, Maria ; Federspiel, Birgitte ; Hasselby, Jane Preuss ; Hansen, Carsten Palnaes ; Kjaer, Andreas ; Knigge, Ulrich. / First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. In: Acta Oncologica. 2012 ; Vol. 51, No. 1. pp. 97-100.
Bibtex
@article{d1a355e469854837a219a7723e03991a,
title = "First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience",
abstract = "Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer.",
author = "Olsen, {Ingrid Holst} and Langer, {Seppo W} and Ida Jepsen and Maria Assens and Birgitte Federspiel and Hasselby, {Jane Preuss} and Hansen, {Carsten Palnaes} and Andreas Kjaer and Ulrich Knigge",
year = "2012",
doi = "10.3109/0284186X.2011.582881",
language = "English",
volume = "51",
pages = "97--100",
journal = "Acta Oncologica",
issn = "1100-1704",
publisher = "Taylor & Francis",
number = "1",
}
RIS
TY - JOUR
T1 - First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience
AU - Olsen, Ingrid Holst
AU - Langer, Seppo W
AU - Jepsen, Ida
AU - Assens, Maria
AU - Federspiel, Birgitte
AU - Hasselby, Jane Preuss
AU - Hansen, Carsten Palnaes
AU - Kjaer, Andreas
AU - Knigge, Ulrich
PY - 2012
Y1 - 2012
N2 - Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer.
AB - Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer.
U2 - 10.3109/0284186X.2011.582881
DO - 10.3109/0284186X.2011.582881
M3 - Journal article
C2 - 21615243
VL - 51
SP - 97
EP - 100
JO - Acta Oncologica
JF - Acta Oncologica
SN - 1100-1704
IS - 1
ER -
